Phase 3 non-inferiority RCT in 536 treatment-naive adults with HIV-1: doravirine-islatravir was non-inferior to bictegravir-emtricitabine-tenofovir alafenamide for HIV-1 RNA <50 copies/mL at week 48 (91.8% vs 90.6%); doravirine resistance arose in 2 participants.
RCTn = 536
Rockstroh et al. Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial